Safety in moderate‐to‐severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti‐tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials

CME Part II Psoriasis: Which Therapy for Which Patient Focus on special populations and chronic infections

(2018) Shivani B. Kaushik et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

(2017) Andrew Blauvelt et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

(2017) Kristian Reich et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics

(2017) Fabrizio Cantini et al.   MEDIATORS OF INFLAMMATION

Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials

(2017) Zheng Zhang et al.   BMJ Open

Management of latentMycobacterium tuberculosisinfection: WHO guidelines for low tuberculosis burden countries

(2015) Haileyesus Getahun et al.   EUROPEAN RESPIRATORY JOURNAL

The Risk of Tuberculosis in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor-  Antagonist: A Metaanalysis of Both Randomized Controlled Trials and Registry/Cohort Studies

(2015) J.-W. Ai et al.   JOURNAL OF RHEUMATOLOGY

Tumor necrosis factor alpha in mycobacterial infection

(2014) Anca Dorhoi et al.   SEMINARS IN IMMUNOLOGY

Risk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in Asia

(2013) Sandra V. Navarra et al.   International Journal of Rheumatic Diseases

The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection

(2012) T.-F. Tsai et al.   BRITISH JOURNAL OF DERMATOLOGY

IL-23 and IL-17 in tuberculosis

(2008) Shabaana A. Khader et al.   CYTOKINE

National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents

(2008) Sean D. Doherty et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review

(2007) Alma Tostmann et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY